In August 2025, the U.S. Department of Commerce did something no federal agency had done before: it opened a Bayh-Dole Act compliance review of a specific university’s entire patent portfolio and asserted the initiation of a march-in proceeding — the government’s rarely-used power to force licensing of federally funded inventions. The target is Harvard University. As of the most recent public reporting available at the time of writing, march-in rights themselves have not been exercised (no license has actually been ordered), but the proceeding is already being described by patent and technology-transfer counsel as the most significant real-world test of the march-in mechanism since the Bayh-Dole Act was enacted in 1980. This page explains what happened, what is and is not yet resolved, and why the outcome matters for every university technology-transfer office, regardless of how it is ultimately decided.
What happened in August 2025
On August 8, 2025, Commerce Secretary Howard Lutnick sent a letter to Harvard University President Alan Garber alleging that Harvard had failed to comply with several requirements of the Bayh-Dole Act (35 U.S.C. §§ 200–212) across its portfolio of federally funded inventions. According to contemporaneous summaries from multiple law firms tracking the matter (Wilson Sonsini, Duane Morris, Kilpatrick Townsend, among others), the letter both raised specific compliance allegations and purported to give Harvard formal notice that a march-in process under Section 203 of the Act was being initiated. Harvard was directed to submit, by September 5, 2025, a detailed report covering all patents arising from federally funded research at the university — including invention-disclosure dates, title-election dates, commercialization status, and licensing terms for each.
Public reporting reviewed for this page does not identify specific named patents or technologies at issue; the request to Harvard was portfolio-wide rather than limited to a single invention or license, which is itself a departure from every prior march-in matter (see below).
What march-in rights are, briefly
Under the Bayh-Dole Act, a university, nonprofit, or small business that elects to retain title to a patentable invention made with federal funding takes on a set of ongoing obligations in exchange — among them, taking effective steps toward commercializing the invention and giving preference to U.S. industry in exclusive licenses. March-in rights (35 U.S.C. § 203) are the enforcement backstop: if the funding agency determines that the title-holder has not met one of four statutory conditions, the agency can require the title-holder to grant a license to a third party on reasonable terms, or grant the license itself. March-in does not transfer patent ownership away from the university; it compels licensing. For the full mechanics, including the four statutory conditions, the petition-decision process, and the appeal path to the Court of Federal Claims, see CASRAI’s guide to Bayh-Dole march-in rights.
The alleged compliance failures
Per the law-firm summaries of the Commerce letter, the allegations against Harvard fall into three categories:
- Untimely invention disclosure and title election. The standard patent rights clause at 37 CFR 401.14 requires a contractor to disclose each subject invention to the funding agency within a set window after an inventor’s internal disclosure, and to elect whether to retain title within a further window after that. Commerce alleged failures on this front across Harvard’s portfolio.
- U.S. industry preference. Section 204 of the Act requires that any exclusive license to sell or use a subject invention in the United States be granted to a licensee that substantially manufactures the resulting product domestically, absent a waiver. Commerce alleged noncompliance with this preference.
- Failure to achieve practical application. Section 203(a)(1) — one of the four statutory march-in conditions — asks whether the title-holder has taken, or is expected to take within a reasonable time, effective steps to achieve practical application of the invention. Commerce alleged that Harvard had not done so for some subject inventions.
Harvard’s substantive response to these specific allegations was not identified in the public reporting reviewed for this page.
Why this differs from every prior march-in matter
March-in rights have existed since 1980, and a small number of petitions asking a funding agency to exercise them have been filed over the decades — most prominently a series of petitions concerning the prostate-cancer drug enzalutamide (Xtandi), beginning in 2016. In every prior instance, the pattern was the same: an outside party (often a patient-advocacy or drug-pricing group) petitioned the funding agency to march in on a specific, already-licensed patent, and the agency declined at the agency-decision stage without a march-in ever actually being granted.
The Harvard matter breaks that pattern in two ways. First, it was not triggered by an outside petition — Commerce itself initiated the compliance review and the march-in notice, unprompted by a third party. Second, it is not scoped to one product or license; Harvard was asked to account for its entire portfolio of federally funded inventions. Commentary from outside patent counsel has also flagged an open legal question worth noting: march-in decisions under the statute are made by the specific federal agency that funded the research at issue (for example, NIH for an NIH-funded invention), not by the Department of Commerce government-wide — Commerce’s role through NIST has traditionally been limited to administering the government-wide implementing regulations (37 CFR Part 401), not exercising march-in itself for other agencies’ funded research. How that jurisdictional question is resolved, if it is contested, may turn out to matter as much as the underlying compliance allegations.
Current status
Based on the most recent legal-industry reporting available at the time of writing (tracking through December 2025), the matter remains at the compliance-review and notice stage: Commerce initiated the process and set a September 5, 2025 deadline for Harvard’s portfolio report, but no march-in license has been reported as actually granted or exercised, and no public information on the substance of Harvard’s response, any negotiated resolution, or a final agency determination was identified in the sources reviewed for this page. Readers should treat “proceeding initiated” and “march-in rights exercised” as distinct claims — as of this writing, only the former has been confirmed; the latter has not happened in the Harvard matter or in any prior march-in matter, ever. This is a genuinely developing story; CASRAI will revisit this page if the status changes.
The Harvard proceeding also arrives against the backdrop of a NIST-proposed Interagency Guidance Framework for Considering the Exercise of March-In Rights, published as a draft Federal Register notice in December 2023 and open for public comment through February 2024 (over 51,000 comments received). That draft framework, which would let agencies weigh price among the factors relevant to the “practical application” and unmet-needs march-in conditions, remained unfinalized as of mid-2026 — not formally withdrawn, but not binding policy either.
Why this matters for the tech-transfer community
Regardless of how the Harvard matter is ultimately resolved, its significance for university technology-transfer offices does not depend on the outcome:
- Compliance-review risk is now real, not theoretical. A federal agency has demonstrated it is willing to open a portfolio-wide Bayh-Dole compliance review of a major research university without a triggering third-party petition. TTOs at other institutions should treat this as a signal to confirm their own invention-disclosure and title-election timelines are documented and defensible.
- iEdison hygiene matters more than ever. Timely, accurate invention disclosure and utilization reporting through the interagency iEdison system is the front-line evidence a TTO would need to produce on short notice if asked. See CASRAI’s guide to iEdison invention reporting.
- Title-election and license-term recordkeeping is now an audit-readiness question, not just a filing task. The 37 CFR 401.14 disclosure and election windows, and the Section 204 U.S.-manufacturing preference in exclusive licenses, are exactly the provisions Commerce cited. CASRAI’s guide to the Bayh-Dole implementing regulations and guide to patent licensing cover the underlying mechanics.
- The precedent value is independent of the result. Even if Commerce ultimately declines to march in — the outcome in every prior matter — the fact that an agency-initiated, portfolio-wide compliance review reached this stage against a major research university is itself a new data point for how march-in and Bayh-Dole compliance oversight can be used going forward.
Frequently asked questions
Has the U.S. government ever actually exercised march-in rights?
Not as of this writing, in the Harvard matter or in any prior matter. Every march-in petition filed since the Bayh-Dole Act’s 1980 enactment has ended with the funding agency declining to march in at the agency-decision stage. The Harvard matter is the first instance of a funding-side agency initiating a march-in proceeding on its own, rather than responding to a third-party petition, and the first scoped to a university’s whole portfolio rather than one product — but it has not resulted in an actually-exercised march-in.
What specific Harvard patents or technologies are involved?
Public reporting reviewed for this page does not name specific patents or technologies. Commerce’s request to Harvard was for a portfolio-wide report of all patents arising from federally funded research, not a request tied to one named invention.
Which federal agency is exercising march-in authority here — Commerce, or Harvard’s actual funding agencies?
This is one of the open questions in the matter. Outside patent counsel have noted that march-in determinations are ordinarily made by the specific agency that funded the research in question, while Commerce (through NIST) has historically administered the government-wide implementing regulations rather than exercising march-in itself. How this is resolved may affect the proceeding’s ultimate legal footing.
Does this affect universities other than Harvard?
Not directly — the compliance review and march-in notice described here are specific to Harvard. Indirectly, technology-transfer offices across the sector have treated it as a signal to review their own invention-disclosure, title-election, and licensing-compliance documentation, given that this is the first time this kind of review has been initiated without a preceding third-party petition.
This page reflects publicly available legal and regulatory reporting on the Harvard matter through the sources available at the time of writing (tracking through December 2025); the proceeding was still pending, with no march-in exercised, as of that reporting. Given the ongoing nature of the matter, readers relying on this for a specific compliance decision should confirm current status directly against Commerce Department and Harvard public statements.
